Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Keiran S M Smalley"'
Autor:
Paulo C Rodriguez, Zhihua Chen, Y Ann Chen, Lilit Karapetyan, Jiannong Li, Manali S Phadke, Jessica K Mandula, Peter A Forsyth, Keiran S M Smalley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Although the anti-PD-1+LAG-3 and the anti-PD-1+CTLA-4 combinations are effective in advanced melanoma, it remains unclear whether their mechanisms of action overlap.Methods We used single cell (sc) RNA-seq, flow cytometry and IHC analysis
Externí odkaz:
https://doaj.org/article/4d56c2e227884da39b33d1663c170b41
Autor:
Nicholas J Taylor, Irina Gaynanova, Steven A Eschrich, Eric A Welsh, Timothy J Garrett, Chris Beecher, Ritin Sharma, John M Koomen, Keiran S M Smalley, Jane L Messina, Peter A Kanetsky
Publikováno v:
PLoS ONE, Vol 15, Iss 10, p e0240849 (2020)
BackgroundMelanoma causes the vast majority of deaths attributable to skin cancer, largely due to its propensity for metastasis. To date, few studies have examined molecular changes between primary cutaneous melanoma and adjacent putatively normal sk
Externí odkaz:
https://doaj.org/article/7e4a93cca33f484ca60e7e32c3f3b2e4
Autor:
Brijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, Mercedes Lioni, Min Xiao, Jun Kong, Clemens Krepler, Adina Vultur, Keith T Flaherty, Katherine L Nathanson, Keiran S M Smalley, Meenhard Herlyn
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e59588 (2013)
Although cyclin dependent kinase (CDK)-2 is known to be dispensable for the growth of most tumors, it is thought to be important for the proliferation of melanoma cells, where its expression is controlled by the melanocyte-lineage specific transcript
Externí odkaz:
https://doaj.org/article/9dce1d95d9e64c5f97be285f194897f0
Autor:
Meghan J. Mooradian, James M. Cleary, Anita Giobbie‐Hurder, Lancia N. F. Darville, Aparna Parikh, Elizabeth I. Buchbinder, Justine V. Cohen, Donald P. Lawrence, Geoffrey I. Shapiro, Harold Keer, Helen X. Chen, Susan Percy Ivy, Keiran S. M. Smalley, John M. Koomen, Ryan J. Sullivan
Publikováno v:
Cancer. 129:1904-1918
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2ec6bc2b1f70e58acff9eae9363547a
https://doi.org/10.1002/cncr.34730
https://doi.org/10.1002/cncr.34730
Autor:
Alcida Karz, Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire, Marcus Bosenberg, Priscilla Brastianos, Daniel P. Cahill, Qing Chen, Sherise Ferguson, Peter Forsyth, Isabella C. Glitza Oliva, Sarah B. Goldberg, Sheri L. Holmen, Jonathan P. S. Knisely, Glenn Merlino, Don X. Nguyen, Michael E. Pacold, Eva Perez‐Guijarro, Keiran S. M. Smalley, Hussein A. Tawbi, Patrick Y. Wen, Michael A. Davies, Harriet M. Kluger, Janice M. Mehnert, Eva Hernando
Publikováno v:
Pigment Cell Melanoma Res
Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent reports on the biology and treatment of melanoma brain m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a94e8e33be51ff0c86a76cfa8c9f04
https://doi.org/10.1111/pcmr.13059
https://doi.org/10.1111/pcmr.13059
Autor:
Sathya Neelature Sriramareddy, Fernanda Faião-Flores, Michael F. Emmons, Biswarup Saha, Srikumar Chellappan, Clayton Wyatt, Inna Smalley, Jonathan D. Licht, Michael A. Durante, J. William Harbour, Keiran S. M. Smalley
Publikováno v:
Cancer Gene Therapy. 29:1840-1846
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e8ba06a0c07b47a2b0cb4333a0f3b42
https://doi.org/10.1038/s41417-022-00452-7
https://doi.org/10.1038/s41417-022-00452-7
Autor:
Zachary J. Thompson, Jamie K. Teer, Jiannong Li, Zhihua Chen, Eric A. Welsh, Yonghong Zhang, Noura Ayoubi, Zeynep Eroglu, Aik Choon Tan, Keiran S. M. Smalley, Yian Ann Chen
Publikováno v:
Cells; Volume 11; Issue 18; Pages: 2894
Although substantial progress has been made in treating patients with advanced melanoma with targeted and immuno-therapies, de novo and acquired resistance is commonplace. After treatment failure, therapeutic options are very limited and novel strate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a52041f26fc599b4626f9a15c8ae19b
https://pubmed.ncbi.nlm.nih.gov/36139469
https://pubmed.ncbi.nlm.nih.gov/36139469
Autor:
Manali S. Phadke, Jiannong Li, Jessica Mandula, Ann Chen, Paulo C. Rodriguez, Keiran S. M. Smalley
Publikováno v:
Cancer Research. 83:5109-5109
Around 40-60% of patients with advanced melanoma develop brain metastases. Recent clinical studies have demonstrated that the efficacy of anti-PD1+anti-LAG3 may be equivalent to anti-PD1+anti-CTLA4. The goal of our project is to understand the mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9af7e8b49e5691ac9b25d5ff52d7aef5
https://doi.org/10.1158/1538-7445.am2023-5109
https://doi.org/10.1158/1538-7445.am2023-5109
Autor:
Vincent Law, Zhihua Chen, Francesca Vena, Inna Smalley, Robert Macaulay, Brittany R Evernden, Nam Tran, Yolanda Pina, John Puskas, Gisela Caceres, Simon Bayle, Joseph Johnson, James K C Liu, Arnold Etame, Michael Vogelbaum, Paulo Rodriguez, Derek Duckett, Brian Czerniecki, Ann Chen, Keiran S M Smalley, Peter A Forsyth
Publikováno v:
Neuro-oncology. 24(10)
Background Leptomeningeal disease (LMD) occurs as a late complication of several human cancers and has no rationally designed treatment options. A major barrier to developing effective therapies for LMD is the lack of cell-based or preclinical models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7906363589680e46c8aa3562a43cd6c0
https://pubmed.ncbi.nlm.nih.gov/35904120
https://pubmed.ncbi.nlm.nih.gov/35904120
Autor:
Sadeeshkumar Velayutham, Trisha Seal, Samaya Danthurthy, Julia Zaias, Keiran S. M. Smalley, Dmitriy Minond
Publikováno v:
Biomolecules. 13:349
Despite the recent advances in melanoma therapy, the need for new targets and novel approaches to therapy is urgent. We previously reported melanoma actives that work via binding and downregulating spliceosomal proteins hnRNPH1 and H2. Given the lack
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0215c04e2cebe29936143f0081a2c679
https://doi.org/10.3390/biom13020349
https://doi.org/10.3390/biom13020349